Sprycel and Reticulocytosis - a phase IV clinical study of FDA data


Reticulocytosis is reported only by a few people who take Sprycel.

The phase IV clinical study analyzes which people take Sprycel and have Reticulocytosis. It is created by eHealthMe based on reports of 25,241 people who have side effects while taking Sprycel from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

25,241 people reported to have side effects when taking Sprycel.
Among them, 3 people (0.01%) have Reticulocytosis.

What is Sprycel?

Sprycel has active ingredients of dasatinib. It is often used in chronic myelogenous leukemia (cml). eHealthMe is studying from 25,387 Sprycel users for its effectiveness, alternative drugs and more.

What is Reticulocytosis?

Reticulocytosis (a condition where there is an increase in reticulocytes) is found to be associated with 225 drugs and 90 conditions by eHealthMe.

Number of Sprycel and Reticulocytosis reports submitted per year:

Could Sprycel cause Reticulocytosis?

Time on Sprycel when people have Reticulocytosis *:

  • < 1 month: 33.33 %
  • 1 - 6 months: 66.67 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Reticulocytosis when taking Sprycel *:

  • female: 66.67 %
  • male: 33.33 %

Age of people who have Reticulocytosis when taking Sprycel *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 33.33 %
  • 60+: 66.67 %

Common side effects people have besides Reticulocytosis *:

  1. Thrombocytopenia (decrease of platelets in blood): 3 people, 100.00%
  2. Microangiopathy (disease of the capillaries (very small blood vessels), in which the capillary walls become so thick and weak that they bleed, leak protein): 3 people, 100.00%
  3. Generalised Oedema (swelling all over the body): 3 people, 100.00%
  4. Disseminated Intravascular Coagulation (systemic activation of blood coagulation): 3 people, 100.00%
  5. Bone Marrow Failure: 3 people, 100.00%
  6. Subarachnoid Haemorrhage (blood leaks into the space between two membranes that surround the brain): 2 people, 66.67%
  7. Nausea (feeling of having an urge to vomit): 2 people, 66.67%
  8. Cerebral Haemorrhage (bleeding within the brain): 1 person, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you take Sprycel and have Reticulocytosis?

Check whether Reticulocytosis is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Reticulocytosis and when was it recovered:

Expand to all the drugs that have ingredients of dasatinib:

Alternative drugs to, pros and cons of Sprycel:

Common Sprycel side effects:

Browse all side effects of Sprycel:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Reticulocytosis treatments and more:

COVID vaccines that are related to Reticulocytosis:

All the drugs that are associated with Reticulocytosis:

All the conditions that are associated with Reticulocytosis:

How the study uses the data?

The study uses data from the FDA. It is based on dasatinib (the active ingredients of Sprycel) and Sprycel (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: